<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03789214</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00198426</org_study_id>
    <secondary_id>UG3DA048734</secondary_id>
    <nct_id>NCT03789214</nct_id>
  </id_info>
  <brief_title>Medical Management of Sleep Disturbance During Opioid Tapering</brief_title>
  <official_title>Medical Management of Sleep Disturbance During Opioid Tapering</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether a dual orexin-receptor antagonist approved by the FDA for&#xD;
      sleep disturbance, suvorexant (SUVO; Belsomra), will increase total sleep time in patients&#xD;
      with opioid use disorder (OUD) undergoing supervised withdrawal. This study is designed as a&#xD;
      dose-finding study of SUVO compared to placebo. Briefly, OUD patients seeking supervised&#xD;
      withdrawal will be admitted into a clinical research unit and stabilized onto buprenorphine&#xD;
      for three days before being randomly assigned to study condition. All participants will then&#xD;
      undergo a routine four-day buprenorphine taper, followed by a four-day post-taper phase.&#xD;
      Participants will be randomized to receive either placebo, Low Dose SUVO, or High Dose SUVO&#xD;
      and the investigators hypothesize that one or both doses of SUVO will improve total sleep&#xD;
      time relative to placebo. Patients will attend a single follow-up session, 5-10 days&#xD;
      following discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time</measure>
    <time_frame>8 nights</time_frame>
    <description>Area-under-the-curve scores of total number of minutes slept per night as measured by a 3-lead wireless electroencephalography and wrist worn actigraphy. Area-under-the-curve scores will represent two time frames: (1) four nights during an opioid taper, and (2) four nights post taper.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Opiate Withdrawal Scale (SOWS)</measure>
    <time_frame>6 days</time_frame>
    <description>Area-under-the-curve of peak daily scores on the SOWS (a 16-item self-reported scale that measures individual opioid withdrawal symptoms using a 0-4 Likert scale; total range of SOWS is 0-64; lower scores indicate mild opioid withdrawal relative to higher scores which indicate more severe opioid withdrawal). Area-under-the-curve scores will represent two time frames: (1) three days during an opioid taper, and (2) three days post taper.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abuse Liability as assessed by visual analogue scale</measure>
    <time_frame>4 nights</time_frame>
    <description>Area-under-the-curve of self-reported feelings of drug &quot;High&quot; on the morning after study drug administration, measured each morning on a 0-100 point visual analogue scale of the question &quot;Last night, did you feel HIGH?&quot;. A score of &quot;0&quot; indicates no abuse liability and a score of 100 indicates extreme abuse liability. This will be assessed over four nights during an opioid taper.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Opioid Dependence</condition>
  <condition>Opioid Withdrawal</condition>
  <condition>Sleep Disturbance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo sleep medication (Placebo oral capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Suvorexant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose sleep medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Suvorexant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose sleep medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo Sleep Medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Suvorexant</intervention_name>
    <description>Low Dose Suvorexant</description>
    <arm_group_label>Low Dose Suvorexant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Suvorexant</intervention_name>
    <description>High Dose Suvorexant</description>
    <arm_group_label>High Dose Suvorexant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years old and above&#xD;
&#xD;
          -  Meets Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for OUD&#xD;
             with evidence of physical dependence on opioids, and seeking treatment to stop using&#xD;
             illicit opioids.&#xD;
&#xD;
          -  Provides a urine sample that tests positive for opioids.&#xD;
&#xD;
          -  Willing to comply with the study protocol.&#xD;
&#xD;
          -  Have no clinically significant chronic medical or surgical disorders or conditions&#xD;
             that are judged by the investigators to prevent participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Seeking or currently enrolled in methadone or buprenorphine maintenance treatment for&#xD;
             OUD&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Have evidence of physical dependence on alcohol or benzodiazepines that requires&#xD;
             medical detoxification&#xD;
&#xD;
          -  Have a known allergy to the study medications&#xD;
&#xD;
          -  Past 30-day prescribed use of suvorexant or benzodiazepines for the indication of&#xD;
             insomnia&#xD;
&#xD;
          -  Current use of a Selective Serotonin Reuptake Inhibitor (SSRI) or Monoamine oxidase&#xD;
             (MAO) inhibitor for depression or insomnia, or other medications that are&#xD;
             contraindicated with suvorexant&#xD;
&#xD;
          -  Current narcolepsy, restless leg syndrome or sleep paralysis&#xD;
&#xD;
          -  High risk for current sleep apnea&#xD;
&#xD;
          -  Current major depressive disorder&#xD;
&#xD;
          -  Past year suicidal behavior&#xD;
&#xD;
          -  Severe hepatic or renal impairment&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) &gt;3x ULN&#xD;
&#xD;
               -  Total bilirubin &gt;2x Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Creatinine &gt;1.5x ULN&#xD;
&#xD;
          -  Have circumstances that would interfere with study participation (e.g., impending&#xD;
             jail)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-reported male or female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S Huhn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2018</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

